Cell Banking Outsourcing MarketSize and Trends

Cell Banking Outsourcing Market – Dynamics

Growing number of stem cell therapies over the recent past, is expected to drive growth of the cell banking outsourcing market. As per survey by World Network for Blood and Marrow Transplantation (WBMN), during 2006–2014, around one million hematopoietic stem cell transplantation were undertaken. These included removing stem cells from bone marrow or peripheral blood and proliferating and storing them in cell banks for later use in patients. Stem cell therapy is applicable for treatment of over 100 diseases currently, as per a report by World Marrow Donor Association, in 2016.

Rising adoption of collaboration and acquisition strategies by the market players is expected to fuel the market growth over the forecast period. For instance, in June 2017, Alligator Bioscience announced partnership with Sartorius Stedim Biotech Group (BioOutsource), as Cell Line Development Partner in its immuno-oncology antibody drug candidate development. In June 2016, BioGenes GmbH announced collaboration with Eurofins Munich, Contract Research Organization for biopharmaceutical product-testing for enhancing the testing of host cell protein (HCP).

Furthermore, increasing research and development in therapy areas such as immunotherapy (Checkpoint Inhibitors, CAR-T, and ACTRC), are being initiated for the treatment of diseases such as cancer. Immunotherapy involves genetically modifying T cells of patients, in vitro proliferation of these cells, storing of these cells in cell banks, further injecting them back into the patient’s body, to produce immune response and kill cancerous cells. Furthermore, increasing demand for biologic products such as vaccines, which involve the use of viral cell banking and viral cell banking safety testing are expected to propel growth of the cell banking outsourcing market.